Thousand Oaks-based Atara Biotherapeutics reported a $58.4 million net loss, or $1.29 per share, as its clinical-stage cancer therapies continued to work their way through trials. Two Phase 3 trials for its product Tab-cel were expanded to new sites in the U.S. and Australia. The company also announced partnerships with Merck and the Moffitt Cancer…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
